BLOOMFIELD HILLS, MI--(Marketwire - July 6, 2012) - Arizona-based algae producer Health Enhancement Products (
The article "ProAlgaZyme and its sub-fractions increase plasma HDL-cholesterol via up regulation of ApoA1, ABCA1 and SRB1 and inhibition of CETP in hypercholesterolemic hamsters," is authored by the team of Andreea Geamanu, Nadia Saadat, Arvind Goja, Monika Wadehra, Xiangming Ji and Smiti V. Gupta, all researchers associated with the Smiti Gupta laboratory at Wayne State University.
"Our data suggests that dietary intake of the algal extract ProAlgaZyme and its specific sub-fractions result in an improved cholesterol distribution in hamsters, primarily via its effects on multiple gene targets in the HDL (or reverse cholesterol transport) pathway," states Dr. Gupta. "Thus the potential for ProAlgaZyme to raise HDL, i.e. the 'good' cholesterol, warrants further investigation."
The article covers more than two years of work conducted by Dr. Gupta and her team. She continues to consult and work with the Company as various compounds and candidate molecules are isolated and analyzed, and is a member of an interdisciplinary working group of scientists and researchers.
Incoming Chief Science Officer Dr. Scott Freeman had this to say: "We congratulate Dr. Gupta and her team for achieving this milestone. These preliminary results commit us to further investigation in order to maximize future market potential."
About Wayne State University
Wayne State University is one of the nation's pre-eminent public research universities in an urban setting, ranking in the top 50 in R & D expenditures of all public universities by the National Science Foundation. Through its multidisciplinary approach to research and education, and its ongoing collaboration with government, industry and other institutions, the university seeks to enhance economic growth and improve the quality of life in the city of Detroit, state of Michigan and throughout the world. For more information about research at Wayne State University, visit http://www.research.wayne.edu.
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.